|本期目录/Table of Contents|

[1]王潜.抗血小板药物在缺血性脑卒中的应用进展[J].慢性病学杂志,2014,(01):63-65.
点击复制

抗血小板药物在缺血性脑卒中的应用进展(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2014年01期
页码:
63-65
栏目:
综述
出版日期:
2014-02-25

文章信息/Info

Title:
-
作者:
王潜
上海市第九人民医院神经内科，上海200011
Author(s):
-
关键词:
抗血小板药物; 脑卒中; 预防; 进展
Keywords:
-
分类号:
R743.3
DOI:
-
摘要:
在我国老龄化趋势日益加速的情况下，脑卒中的危害日益突出，对脑卒中的预防已经成为卫生工作的 重要课题之一，也越来越引起国内外医学界特别是神经科学界的重视，而抗血小板药物是预防脑卒中的重 要手段之一。本文对抗血小板药物在缺血性脑卒中的应用进展进行综述。
Abstract:
-

参考文献/References:

[1] 李焰生. 扩大时间窗溶栓:急性卒中治疗13年来最大的进步 ——欧洲协作性急性卒中研究-3(ECASS3)结果解读［J］．中 国卒中杂志，2009，4(1):102-106.
[2］ 刘福贤.缺血性脑卒中的临床和预后分析［D］．长春：吉林大 学，2005.
[3］ 中华医学会神经病学分会脑血管病学组，缺血性脑卒中二级预 防指南撰写组.中国缺血性脑卒中和短暂性脑缺血发作二级预 防指南（2010）［J］．中国临床医生，2011，39(11):1240-1249.
[4］ 陈怀珍.《急性缺血性脑血管病中西医诊疗指南》解读［J］．中 医药临床，2013，25(11):941-945.
[5］ Algra A, van Gijn J . Cumulative meta-analysis of aspirin effi? cacy after cerebral ischaemia of arterial origin［J］．J NeurolNeurosurg Psychiatry ,1999,66(2):255.
[6］Patrono C, Garcia Rodriguez LA, Landolfi R,et al. Low-dose aspirin for the prevention of atherothrombosis［J］．N EnglJ Med,2005,353(22):2373-2383.
[7］Campbell CL, Smyth S, Montalescot G,et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review ［J］．JAMA,2007,297(18):2018-2024.
[8］The Dutch TIA Trial Study Group . A comparison of two dos? es of aspirin (30mg vs.283mg a day) in patients after a tran? sient ischemic attack or minor ischemic stroke［J］．N Engl J Med,1991,325(18):1261-1266.
[9］Farrell B, Godwin J, Richards S,et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results ［J］．J NeurolNeurosurg Psychiatry ,1991,54(12):1044-1054.
[10］Diener HC, Bogousslavsky J, Brass LM,et al.Aspirin and? clopidogrel compared with clopidogrel alone after recent isch? aemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double- blind, placebo- controlled trial［J］．Lancet,2004,364(9431):331-337.
[11］Bhatt DL, Flather MD, Hacke W,et al. Patients with prior myocardialinfarction, stroke, or symptomatic peripheralarteri? al disease in the CHARISMA trial［J］．J Am Coll Cardiol, 2007,49(19):1982-1988.
[12］Diener HC, Cunha L, Forbes C,et al. European Stroke Pre? vention Study.2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke［J］．J Neurol Sci, 1996,143 (1-2):1-13.
[13］Diener HC, Darius H, Bertrand- Hardy JM,et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2) ［J］．IntJ Clin Pract,2001,55(3):162-163.
[14］Hart RG, Pearce LA, Aguilar MI . Meta-analysis: antithrom? botic therapy to prevent stroke inpatients who have nonvalvular atrialfibrillation［J］．AnnInternMed,2007,146(12):857–867.
[15］Gross CP, Vogel EW, Dhond AJ,et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvu? lar atrial fibrillation: a cross-sectional survey［J］．Clin Ther, 2003,25(6):1750-1764.
[16］Connolly SJ, Pogue J, Hart RG,et al. Effect ofclopidogrel added to aspirin in patients with atrial fibrillation［J］．N Engl J Med,2009,360(20):2066-2078.
[17］Albers GW, Amarenco P, Easton JD,et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8thedition) ［J］．Chest,2008,133(6suppl):630S-669S.
[18］International Stroke Trial Collaborative Group. The Interna? tional Stroke Trial (IST):arandomisedtrialofaspirin,subcuta? neousheparin,both,orneitheramong19435patientswithacute ischaemicstroke［J］．Lancet,1997,349(9065):1569-1581.
[19］ CAST(Chinese Acute Stroke Trial)Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000patients with acute ischaemic stroke［J］．Lancet, 1997;349(9066):1641-1649.
[20］Patrono C, Garcia Rodriguez LA, Landolfi R,et al. Low-dose aspirin for the prevention of atherothrombosis［J］．N Engl J Med ,2005,353(22):2373-2383.
[21］Hankey GJ, Eikelboom JW . Aspirin resistance［J］．Lancet, 2006,367(9510):606-617.
[22］Breet NJ, van Werkum JW, Bouman HJ,et al. Comparison of platelet function tests in predicting clinical outcome in pa? tients undergoing coronary stent implantation ［J］．JAMA, 2010,303(8):754-762.
[23］Hills NK, Johnston SC. Trends in usage of alternative anti? platelet therapy after stroke and transient ischemic attack［J］． Stroke,2008,39(4):1228-1232.
[24］Kwon SU, Cho YJ, Koo JS,et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilo? stazolin symptomatic intracranialarterialstenosis［J］．Stroke, 2005,36(4):782-786.
[25］Shinohara Y, Nishimaru K, Sawada T,et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): a randomized, double- blind, aspirin- controlled trial ［J］． Stroke ,2008,39(6):1827-1833.

备注/Memo

备注/Memo:
作者简介：王潜，硕士，住院医师，主要从事神经内科的临 床诊疗工作 通信作者：王潜，E-mail：wangq812114@163.com
更新日期/Last Update: 2014-01-30